glp-1 without diabetes Receptor Agonists and Research to Treat Overeating and Substance Use Disorders GLP-1 agonists and changes in

In a review of racial and ethnic differences in obesity outcomes of lifestyle, surgical, and pharmacological interventions published between 2000 and 2022, lower efficacy of lifestyle and surgical interventions was commonly identified among Black compared with White participants (with no or smaller differences for Hispanic compared with White participants)

Pills are likely to be strongest in early treatment, needle-averse patients, maintenance therapy, and broad access markets

Retatrutide (LY3437943): This Lilly molecule is a triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors (so called Triple G)

[DOI] [PubMed] [Google Scholar] 77.Hunt J.E., Holst J.J., Jeppesen P.B., Kissow H